TriangleObinutuzumab (NCT06806033)
Obinutuzumab trial for Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NCT06806033). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with selected aggressive B-cell lymphomas that returned or resisted treatment. At least one previous treatment is required; after only one, patients must be transplant-ineligible and enter the combination group.
The idea: glofitamab connects T cells with CD20-bearing lymphoma cells. After obinutuzumab, one group receives glofitamab with gemcitabine and oxaliplatin, then glofitamab alone; another receives glofitamab alone. The study tests steroid preparation and outpatient monitoring to reduce cytokine-release reactions. Previous CD20/CD3 bispecific treatment is excluded.
This phase 2 study plans 130 patients. Roche sponsors thirty-three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.